Keyword: Steven Benner

Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.

Pfizer, Astellas and J&J envision a wide-open field for patients whose prostate cancer hasn't spread. But there's a high-stakes market scrum ahead.

After Johnson & Johnson's Zytiga put up notable prostate cancer data, Astellas and Pfizer needed a win for their medicine Xtandi. Now they have one.